<DOC>
	<DOCNO>NCT00093678</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may help relieve moderate severe pain associated cancer . It may also decrease weight loss improve muscle strength cancer patient . PURPOSE : This randomized clinical trial study celecoxib see well work manage pain , weight loss , weakness patient advance cancer .</brief_summary>
	<brief_title>Celecoxib Managing Pain , Weight Loss , Weakness Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare symptom burden functional status , measure physical well-being subscale Functional Assessment Cancer Therapy-General ( FACT-G ) , patient advance cancer treat celecoxib v placebo . Secondary - Compare pain , measure Brief Pain Inventory , patient treat drug . - Compare need opioid analgesic , measure oral morphine equivalent analgesic use , patient treat drug . - Compare weight loss patient treat drug . - Compare quality life , measure FACT-G , patient treat drug . - Compare median survival patient treat drug . - Determine toxicity celecoxib patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord ECOG performance status ( 0 1 v 2 3 ) , need opioid analgesic within past 2 week ( yes v ) , weight loss percentage baseline body weight ( &lt; 5 % v ≥ 5 % ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral celecoxib twice daily . - Arm II : Patients receive oral placebo twice daily . In arm , treatment continue absence unacceptable toxicity . Quality life assess baseline 2 , 6 , 12 week . Patients follow every 3 month 2 year every 6 month 1 year . PROJECTED ACCRUAL : A total 296 patient ( 148 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignant tumor 1 follow type : Carcinoma Sarcoma Melanoma Lymphoma Metastatic unresectable disease Clear evidence residual disease recent prior treatment Measurable disease require Patient elect receive supportive care rather active cancer treatment ( e.g. , palliative chemotherapy ) Brain metastasis allow provide follow criterion meet : Completed treatment CNS disease ( e.g. , whole brain radiotherapy , surgery , stereotactic surgery ) Clinically stable disease least 4 week treatment completion No requirement corticosteroid PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 03 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) ALT AST ≤ 5 time ULN Renal Creatinine ≤ 1.6 mg/dL Cardiovascular No myocardial infarction within past 6 month No transient ischemic attack within past 6 month No stroke within past 6 month No angina pectoris require medical therapy No active coronary artery disease cerebrovascular disease Other No active gastrointestinal ( GI ) ulcer disease No GI bleed No history allergic reaction , urticaria , bronchospasm take NSAIDs , aspirin , sulfonamide drug Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Concurrent hematopoietic growth factor cytopenia fatigue allow No concurrent biologic anticancer agent Chemotherapy See Disease Characteristics Endocrine therapy See Disease Characteristics No concurrent corticosteroid management cancerrelated symptom illness No concurrent hormonal therapy Concurrent luteinizing hormonereleasing hormone therapy allow prostate cancer patient provide drug initiate least 6 month ago AND unequivocal evidence progressive disease , define 1 follow criterion : Rising prostatespecific antigen ( PSA ) 3 successive measurement Rising PSA 2 measurement take least 2 week apart New lesion bone scan Radiotherapy See Disease Characteristics Surgery See Disease Characteristics Other Concurrent bisphosphonates management osseous metastasis hypercalcemia allow No concurrent cytotoxic drug No concurrent nonsteroidal antiinflammatory drug ( NSAIDs ) aspirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>pain</keyword>
	<keyword>cachexia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>chondrosarcoma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>classic Kaposi sarcoma</keyword>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>primary central nervous system lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>immunosuppressive treatment relate Kaposi sarcoma</keyword>
</DOC>